Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Published:2012-03-31 Issue:7 Volume:87 Page:687-691
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Jabbour Elias J.,Kantarjian Hagop,Eliasson Lina,Megan Cornelison A.,Marin David

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23180/fullpdf

Reference25 articles.

1. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors;Robin;Leukemia,2005

2. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective;Tomblyn;Biol Blood Marrow Transplant,2009

3. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood (ASH Annual Meeting Abstracts),2009

4. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib;Marin;J Clin Oncol,2010

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer: SAMSON Pilot Randomized Controlled Trial (Preprint);2024-08-12

2. Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?;The AAPS Journal;2024-06-11

3. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

4. Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia;International Immunopharmacology;2023-11

5. Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia;Journal of Oncology Pharmacy Practice;2023-09-25